Restricted accessReview articleFirst published online 2012-2
The Canadian Network for Mood and Anxiety Treatments (Canmat) Task Force Recommendations for the Management of Patients with Mood Disorders and Select Comorbid Medical Conditions
Medical comorbidity in patients with mood disorders has become an increasingly important clinical and global public health issue. Several specific medical conditions are associated with an increased risk of mood disorders, and conversely, mood disorders are associated with increased morbidity and mortality in patients with specific medical disorders.
Methods
To help understand the bidirectional relationship and to provide an evidence-based framework to guide the treatment of mood disorders that are comorbid with medical illness, we have reviewed relevant articles and reviews published in English-language databases (to April 2011) on the links between mood disorders and several common medical conditions, evaluating the efficacy and safety of pharmacologic and psychosocial treatments. The medical disorders most commonly encountered in adult populations (ie, cardiovascular disease, cerebrovascular disease, cancer, human immunodeficiency virus, hepatitis C virus, migraine, multiple sclerosis, epilepsy, and osteoporosis) were chosen as the focus of this review.
Results
Emerging evidence suggests that depression comorbid with several medical disorders is treatable and failure to treat depression in medically ill patients may have a negative effect on medical outcomes.
Conclusions
This review summarizes the available evidence and provides treatment recommendations for the management of comorbid depression in medically ill patients.
ThombsBD, BassEB, FordDE, . Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006;21:30–38.
2.
RudischB, NemeroffCB.Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54:227–240.
3.
RuguliesR.Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002;23:51–61.
4.
NicholsonA, KuperH, HemingwayH.Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J.2006;27:2763–2774.
5.
LaursenTM, Munk-OlsenT, NordentoftM, . Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68:899–907.
6.
AntmanEM, AnbeDT, ArmstrongPW, . ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1–E211.
7.
AndersonJL, AdamsCD, AntmanEM, ; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116: e148–e304.
8.
GibbonsRJ, AbramsJ, ChatterjeeK, ; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159–168.
9.
LichtmanJH, BiggerJTJr, BlumenthalJA, ; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118:1768–1775.
10.
Frasure-SmithN, LespéranceF, PrinceRH, . Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet. 1997;350:473–479.
SaabPG, BangH, WilliamsRB, . The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. J Psychosom Res. 2009;67:45–56.
13.
LindenW, StosselC, MauriceJ.Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996;156:745–752.
14.
DusseldorpE, van ElderenT, MaesS, . A metaanalysis of psychoeducational programs for coronary heart disease patients. Health Psychol. 1999;18:506–519.
15.
LindenW, PhillipsMJ, LeclercJ.Psychological treatment of cardiac patients: a meta-analysis. Eur Heart J.2007;28:2972–2984.
16.
StrikJJ, HonigA, LousbergR, . Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783–789.
17.
GlassmanAH, O'ConnorCM, CaliffRM, ; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–709.
18.
LespéranceF, Frasure-SmithN, KoszyckiD, ; CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367–379.
19.
HonigA, KuyperAM, ScheneAH, ; MIND-IT investigators. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69:606–613.
20.
ThombsBD, de JongeP, CoyneJC, . Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300:2161–2171.
21.
CarneyRM, FreedlandKE, MillerGE, . Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53:897–902.
22.
ThomasAJ, KalariaRN, O'BrienJT.Depression and vascular disease: what is the relationship?J Affect Disord.2004;79:81–95.
23.
Everson-RoseSA, LewisTT.Psychosocial factors and cardiovascular diseases. Annu Rev Public Health. 2005;26:469–500.
24.
LaursenTM, Munk-OlsenT, AgerboE, . Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009;66:713–720.
TaylorCB, ConradA, WilhelmFH, . Psychophysiological and cortisol responses to psychological stress in depressed and nondepressed older men and women with elevated cardiovascular disease risk. Psychosom Med. 2006;68:538–546.
27.
PollockBG, Laghrissi-ThodeF, WagnerWR.Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20:137–140.
28.
SerebruanyVL, GlassmanAH, MalininAI, . Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis. 2003;14:563–567.
29.
SherwoodA, HinderliterAL, WatkinsLL, . Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol. 2005;46:656–659.
30.
LespéranceF, Frasure-SmithN, ThérouxP, . The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry. 2004;161:271–277.
31.
EmpanaJP, SykesDH, LucG, ; PRIME Study Group. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2005;111:2299–2305.
32.
RobinsonRG, SpallettaG.Poststroke depression: a review. Can J Psychiatry. 2010;55:341–349.
RamasubbuR.Relationship between depression and cerebrovascular disease: conceptual issues. J Affect Disord. 2000;57:1–11.
37.
RobinsonRG.Post stroke mania: prevalence and clinical symptoms. In: RobinsonRG.The clinical neuropsychiatry of stroke: cognitive, behavioral, and emotional disorders following vascular brain injury. Cambridge, United Kingdom: Cambridge University Press; 1998:303–312.
38.
BurvillPW, JohnsonGA, JamrozikKD, . Prevalence of depression after stroke: the Perth Community Stroke Study. Br J Psychiatry. 1995;166:320–327.
39.
ParikhRM, RobinsonRG, LipseyJR, . The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990;47:785–789.
MorrisPL, RobinsonRG, SamuelsJ.Depression, introversion and mortality following stroke. Aust N Z J Psychiatry. 1993;27:443–449.
42.
StenagerEN, MadsenC, StenagerE, . Suicide in patients with stroke: epidemiological study. BMJ. 1998;316:1206.
43.
RamasubbuR, PattenSB.Effect of depression on stroke morbidity and mortality. Can J Psychiatry. 2003;48:250–257.
44.
LarsonSL, OwensPL, FordD, . Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001;32:1979–1983.
RamasubbuR, TobiasR, Bech-HansenNT.Extended evaluation of serotonin transporter gene functional polymorphisms in subjects with post-stroke depression. Can J Psychiatry. 2008;53:197–201.
47.
KohenR, CainKC, MitchellPH, . Association of serotonin transporter gene polymorphisms with poststroke depression. Arch Gen Psychiatry. 2008;65:1296–1302.
48.
SpallettaG, BossùP, CiaramellaA, . The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry. 2006;11:984–991.
49.
RobinsonRG.Mechanisms of post stroke depression. In: RobinsonRG.The clinical neuropsychiatry of stroke: cognitive, behavioral, and emotional disorders following vascular brain injury. Cambridge, United Kingdom: Cambridge University Press; 1998:254–281.
TenevVT, RobinsonRG, JorgeRE.Is family history of depression a risk factor for poststroke depression? Meta-analysis. Am J Geriatr Psychiatry. 2009;17:276–280.
52.
HackettML, AndersonCS, HouseA, . Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;CD003437.
53.
ChenY, GuoJJ, ZhanS, . Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006;40:2115–2122.
54.
AndersonG, VestergaardK, LauritzenL.Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099–1104.
55.
WiartL, PetitH, JosephPA, . Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829–1832.
56.
RobinsonRG, SchultzSK, CastilloC, . Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–359.
57.
FruehwaldS, GatterbauerE, RehakP, . Early fluoxetine treatment of post-stroke depression–a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347–351.
58.
MurrayV, von ArbinM, BartfaiA, . Doubleblind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry. 2005;66:708–716.
59.
LipseyJR, RobinsonRG, PearlsonGD, . Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984;1:297–300.
60.
GradeC, RedfordB, ChrostowskiJ, . Methylphenidate in early poststroke recovery: a doubleblind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047–1050.
61.
HackettML, AndersonCS, HouseA, . Interventions for preventing depression after stroke. Cochrane Database Syst Rev. 2008;CD003689.
62.
ChenY, PatelNC, GuoJJ, . Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–166.
63.
YiZM, LiuF, ZhaiSD.Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. Int J Clin Pract. 2010;64:1310–1317.
64.
RobinsonRG, JorgeRE, MoserDJ, . Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391–2400.
65.
FullertonAG, AgerholmM.Side-effects of nortriptyline treatment for poststroke depression. Lancet. 1984;323:519–520.
66.
JiangB, LuW, SongX-W, . The effect of post stroke depression interventions on the recovery of neurological function. Modern Rehabilitation. 2001;5:29–30. 67.
67.
RampelloL, AlvanoA, ChiechioS, . An evaluation of efficacy and safety of reboxetine in elderly patients affected by “retarded” post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr. 2005;40:275–285.
68.
RedingMJ, OrtoLA, WinterSW, . Antidepressant therapy after stroke. A double-blind trial. Arch Neurol. 1986;43:763–765.
69.
DeVaneCL, MarkowitzJS.Avoiding psychotropic drug interactions in the cardiovascular patient. Bull Menninger Clin. 2000;64:49–59.
70.
SacchettiE, TurrinaC, ValsecchiP.Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf. 2010;33:273–288.
JorgeRE, RobinsonRG, TatenoA, . Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry. 2004;55:398–405.
73.
LoC, LiM, RodinG.The assessment and treatment of distress in cancer patients: overview and future directions. Minerva Psichiatr. 2008;49:129–143.
74.
MassieMJ.Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004:57–71.
75.
Brintzenhofe-SzocKM, LevinTT, LiY, . Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009;50:383–391.
76.
RodinG, ZimmermannC, RydallA, . The desire for hastened death in patients with metastatic cancer. J Pain Symptom Manage. 2007;33:661–675.
77.
PirlWF.Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;32:32–39.
78.
LoC, ZimmermannC, RydallA, . Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol. 2010;28:3084–3089.
79.
BentonT, StaabJ, EvansDL.Medical comorbidity in depressive disorders. Ann Clin Psychiatry. 2007;19:289–303.
80.
ClarkeDM, Currie DepressionKC., anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust.2009;190:S54–S60.
81.
KesslerRC, BerglundP, DemlerO, . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.
82.
GrassiL, IndelliM, MarzolaM, . Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage. 1996;12:300–307.
ColleoniM, MandalaM, PeruzzottiG, . Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326–1327.
85.
ChenML, ChangHK.Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med. 2004;18:712–718.
86.
PrietoJM, BlanchJ, AtalaJ, . Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20:1907–1917.
87.
PinquartM, DubersteinPR.Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40:1797–1810.
88.
SatinJR, LindenW, PhillipsMJ.Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009;115:5349–5361.
89.
Lloyd-WilliamsM, ShielsC, TaylorF, . Depression—an independent predictor of early death in patients with advanced cancer. J Affect Disord. 2009;113:127–132.
90.
IosifescuDV.Treating depression in the medically ill. Psychiatr Clin North Am. 2007;30:77–90.
GarssenB.Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev. 2004;24:315–338.
93.
NausheenB, CarrNJ, PevelerRC, . Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum. Psychosom Med. 2010;72:912–916.
94.
MillerAH, Ancoli-IsraelS, BowerJE, . Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26:971–982.
95.
JacobsenPB, DonovanKA, SwaineAN, . Management of anxiety and depression in adult cancer patients: toward an evidence-based approach. In: ChangAE, GanzPA, KinsellaTJ, , eds. Oncology: an evidence-based approach.New York, NY: SpringerVerlag; 2006:1552–1579.
96.
WilliamsS, DaleJ.The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372–390.
97.
RodinG, LloydN, KatzM, . The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15:123–136.
98.
NgCG, BoksMP, ZainalNZ, . The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord. 2010;131:1–7.
99.
JacobsenPB, JimHS.Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin.2008;58:214–230.
100.
SheardT, MaguireP.The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999;80:1770–1780.
101.
AndrykowskiMA, ManneSL.Are psychological interventions effective and accepted by cancer patients? I. Standards and levels of evidence. Ann Behav Med. 2006;32:93–97.
102.
LeporeSJ, CoyneJC.Psychological interventions for distress in cancer patients: a review of reviews. Ann Behav Med. 2006;32:85–92.
103.
HiemkeC, HartterS.Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11–28.
104.
MorrowGR, HickokJT, RoscoeJA, . Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21:4635–4641.
105.
MusselmanDL, LawsonDH, GumnickJF, . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966.
106.
RoscoeJA, MorrowGR, HickokJT, . Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005;89:243–249.
107.
PezzellaG, Moslinger-GehmayrR, ContuA.Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat. 2001;70:1–10.
108.
MusselmanDL, SomersetWI, GuoY, . A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry. 2006;67:288–296.
109.
NavariRM, BrennerMC, WilsonMN.Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008;112:197–201.
110.
RazaviD, AllilaireJF, SmithM, . The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand. 1996;94:205–210.
111.
HollandJC, RomanoSJ, HeiligensteinJH, . A controlled trial of fluoxetine and desipra-mine in depressed women with advanced cancer. Psychooncology. 1998;7:291–300.
112.
FischMJ, LoehrerPJ, KristellerJ, . Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21:1937–1943.
113.
LydiattWM, DenmanD, McNeillyDP, . A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134:528–535.
114.
CostaD, MogosI, TomaT.Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand. 1985;320:85–92.
115.
van HeeringenK, ZivkovM.Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry. 1996;169:440–443.
116.
TarrierN, MaguireP.Treatment of psychological distress following mastectomy: an initial report. Behav Res Ther. 1984;22:81–84.
117.
ErsoyMA, NoyanAM, ElbiH.An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. Clin Drug Investig. 2008;28:113–120.
118.
KimSW, ShinIS, KimJM, . Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62:75–83.
119.
MossEL, SimpsonJS, PelletierG, . An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15:259–267.
120.
HollandJC, MorrowGR, SchmaleA, . A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol. 1991;9:1004–1011.
121.
WaldTG, KatholRG, NoyesRJr, . Rapid relief of anxiety in cancer patients with both alprazolam and placebo. Psychosomatics. 1993;34:324–332.
122.
BrueraE, RocaE, CedaroL, . Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69:751–754.
123.
FernandezF, AdamsF, HolmesVF, . Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics. 1987;28:455–461.
124.
HomsiJ, NelsonKA, SarhillN, . A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001;18:403–407.
125.
MacleodAD.Methylphenidate in terminal depression. J Pain Symptom Manage. 1998;16:193–198.
126.
OlinJ, MasandP.Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37:57–62.
127.
NatenshonAL.Clinical evaluation of Ritalin. Dis Nerv Syst. 1956;17:392–396.
128.
BrueraE, CarraroS, RocaE, . Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients. Cancer Treat Rep. 1986;70:295–298.
129.
ArakawaS.Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. Cancer Nurs. 1997;20:342–349.
130.
BindemannS, SoukopM, KayeSB.Randomised controlled study of relaxation training. Eur J Cancer. 1991;27:170–174.
131.
EdgarL, RosbergerZ, ColletJP.Lessons learned: Outcomes and methodology of a coping skills intervention trial comparing individual and group formats for patients with cancer. Int J Psychiatry Med. 2001;31:289–304.
132.
FawzyFI, KemenyME, FawzyNW, . A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry. 1990;47:729–735.
133.
PetersenRW, QuinlivanJA.Preventing anxiety and depression in gynaecological cancer: a randomised controlled trial. BJOG. 2002;109:386–394.
134.
AndoM, MoritaT, AkechiT, . The efficacy of mindfulness-based meditation therapy on anxiety, depression, and spirituality in Japanese patients with cancer. J Palliat Med. 2009;12:1091–1094.
135.
BurishTG, CareyMP, KrozelyMG, . Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol. 1987;55:42–48.
136.
BurishTG, LylesJN.Effectiveness of relaxation training in reducing adverse reactions to cancer chemotherapy. J Behav Med. 1981;4:65–78.
137.
JacobsenPB, MeadeCD, SteinKD, . Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol. 2002;20:2851–2862.
138.
MantovaniG, AstaraG, LampisB, . Evaluation by multidimensional instruments of health-related quality of life of elderly cancer patients undergoing three different “psychosocial” treatment approaches. A randomized clinical trial. Support Care Cancer. 1996;4:129–140.
139.
DeckerTW, Cline-ElsenJ, GallagherM.Relaxation therapy as an adjunct in radiation oncology. J Clin Psychol. 1992;48:388–393.
140.
EvansRL, ConnisRT.Comparison of brief group therapies for depressed cancer patients receiving radiation treatment. Public Health Rep. 1995;110:306–311.
141.
PruittBT, Waligora-SerafinB, McMahonT, . An educational intervention for newly-diagnosed cancer patients undergoing radiotherapy. Psychooncology. 1993;2:55–62.
142.
SimpsonJS, CarlsonLE, TrewME.Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 2001;9:19–26.
143.
LiossiC, WhiteP.Efficacy of clinical hypnosis in the enhancement of quality of life of terminally ill cancer patients. Contemp Hypn. 2001;18:145–160.
144.
McQuellonRP, WellsM, HoffmanS, . Reducing distress in cancer patients with an orientation program. Psychooncology. 1998;7:207–217.
145.
McArdleJM, GeorgeWD, McArdleCS, . Psychological support for patients undergoing breast cancer surgery: a randomised study. BMJ (Clinical research ed). 1996;312:813–816.
146.
RawlSM, GivenBA, GivenCW, . Intervention to improve psychological functioning for newly diagnosed patients with cancer. Oncol Nurs Forum. 2002;29:967–975.
147.
WatsonM, DentonS, BaumM, . Counselling breast cancer patients: a specialist nurse service. Couns Psychol Quart. 1988;1:25–34.
148.
KissaneDW, GrabschB, ClarkeDM, . Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology. 2007;16:277–286.
149.
EdelmanS, BellDR, KidmanAD.A group cognitive behaviour therapy programme with metastatic breast cancer patients. Psychooncology. 1999;8:295–305.
150.
GoodwinPJ, LeszczM, EnnisM, . The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345:1719–1726.
151.
PitceathlyC, MaguireP, FletcherI, . Can a brief psychological intervention prevent anxiety or depressive disorders in cancer patients? A randomised controlled trial. Ann Oncol. 2009;20:928–934.
152.
MarchioroG, AzzarelloG, ChecchinF, . The impact of a psychological intervention on quality of life in non-metastatic breast cancer. Eur J Cancer. 1996;32A:1612–1615.
153.
SavardJ, SimardS, GiguereI, . Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care. 2006;4:219–237.
BrownGR, RundellJR, McManisSE, . Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med. 1992;54:588–601.
156.
DewMA, BeckerJT, SanchezJ, . Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluation. Psychol Med. 1997;27:395–409.
157.
AvantsSK, MargolinA, WarburtonLA, . Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict. 2001;10:69–78.
158.
TuckerJS, BurnamMA, SherbourneCD, . Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–580.
159.
IckovicsJR, HamburgerME, VlahovD, . Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466–1474.
FerrandoSJ, GoldmanJD, CharnessWE.Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psych. 1997;19:89–97.
162.
MarkowitzJC, KocsisJH, FishmanB, . Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry. 1998;55:452–457.
163.
AtkinsonJH, HeatonRK, PattersonTL, . Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord. 2008;108:225–234.
164.
AlciatiA, GalloL, MonforteAD, . Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol. 2007;22:33–40.
165.
EvansDL, Ten HaveTR, DouglasSD, . Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 2002;159:1752–1759.
166.
LochetP, PeyriereH, LottheA, . Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4:62–66.
167.
O'MahonySM, MyintAM, SteinbuschH, . Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation. 2005;12:293–298.
168.
HimelhochS, MedoffDR.Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS.2005;19:813–822.
169.
RabkinJG, RabkinR, HarrisonW, . Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry. 1994;151:516–523.
170.
FernandezF, LevyJK, SamleyHR, . Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med. 1995;25:53–67.
171.
WagnerGJ, RabkinR.Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000;61:436–440.
172.
RabkinJG, McElhineyMC, RabkinR, . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry. 2010;71:707–715.
173.
ElliottAJ, UldallKK, BergamK, . Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998;155:367–372.
174.
SchwartzJA, McDanielJS.Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety. 1999;9:70–74.
175.
CurrierMB, MolinaG, KatoM.Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics. 2004;45:210–216.
176.
RabkinJG, WagnerG, RabkinR.Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry. 1994;55:433–439.
177.
GutierrezMM, RosenbergJ, AbramowitzW.An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003;25:1200–1210.
178.
ChesneyMA, ChambersDB, TaylorJM, . Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med. 2003;65:1038–1046.
179.
KellyJA, MurphyDA, BahrGR, . Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry. 1993;150:1679–1686.
180.
MarkowitzJC, KlermanGL, CloughertyKF, . Individual psychotherapies for depressed HIV-positive patients. Am J Psychiatry. 1995;152:1504–1509.
181.
Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341–344.
182.
ShermanM, ShafranS, BurakK, . Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007;21:(suppl C)25C–34C.
183.
StraderDB, WrightT, ThomasDL, . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171.
184.
el-SeragHB, KunikM, RichardsonP, . Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476–482.
185.
WichersMC, KoekGH, RobaeysG, . IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10:538–544.
186.
CapuronL, PagnoniG, DemetrashviliM, . Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry. 2005;58:190–196.
187.
WichersMC, KenisG, KoekGH, . Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res. 2007;62:207–214.
188.
GleasonOC, YatesWR, IsbellMD, . An openlabel trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194–198.
189.
GleasonOC, YatesWR, PhilipsenMA.Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry. 2005;7:225–230.
190.
MorascoBJ, RifaiMA, LoftisJM, . A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103:83–90.
191.
RaisonCL, WoolwineBJ, DemetrashviliMF, . Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25:1163–1174.
192.
KronenbergerB, BergT, HerrmannE, . Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, doubleblind trial. Eur J Gastroenterol Hepatol. 2007;19:639–646.
193.
QuarantiniLC, Miranda-ScippaA, SchinoniMI, . Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol. 2006;29:138–143.
194.
SchrammTM, LawfordBR, MacdonaldGA, . Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359–361.
195.
KalyoncuOA, TanD, MirsalH, . Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol. 2005;19:102–105.
196.
LevensonJL, FallonHJ.Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88:760–761.
197.
GoldmanSL.Successful treatment of interferon-alfa-induced depression treated with nortriptyline (letter). Psychosomatics. 1994;35:412–413.
198.
GleasonOC, YatesWR.Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999;40:510–512.
199.
Malek-AhmadiP, GhandourE.Bupropion for treatment of interferon-induced depression. Ann Pharmacother. 2004;38:1202–1205.
200.
ICHD-II. The International Classification of Headache Disorders. 2nd ed.Cephalalgia.2004;24:8–160. 201.
201.
MerikangasKR, StevensDE.Comorbidity of migraine and psychiatric disorders. Neurol Clin. 1997;15:115–123.
202.
BreslauN, DavisG, SchultzL, . Migraine and major depression: a longitudinal study. Headache. 1994;34:387–393.
203.
BreslauN.Psychiatric comorbidity in migraine. Cephalalgia. 1998;18:(suppl 22)56–58.
204.
BreslauN, LiptonR, StewartW, . Comorbidity of migraine and depression. Investigating potential etiology and prognosis. Neurology. 2003;60:1308–1312.
205.
MerikangasKR, StevensDE, AngstJ.Psychopathology and headache syndromes in the community. Headache.1994;34:S17–S22.
206.
MerikangasKR, AngstJ, IslerH.Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry. 1990;47:849–853.
207.
MerikangasKR, RischNJ, MerikangasJR, . Migraine and depression: association and familial transmission. J Psychiatr Res. 1988;22:119–129.
208.
LiptonR, HamelskyS, KolodnerK, . Migraine, quality of life, and depression. Neurology. 2000;55:629–635.
209.
BreslauN, Davis MigraineGC., physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res. 1993;27:211–221.
210.
StewartWF, ShechterA, LibermanJ.Physician consultation for headache pain and history of panic: results from a population-based study. Am J Med. 1992;92:35–40.
BreslauN, SchultzL, StewartW, . Headache and major depression: is the association specific to migraine?Neurology. 2000;54:308–313.
213.
RadatF, SwendsenJ.Psychiatric comorbidity in migraine: a review. Cephalalgia. 2005;25:165–178.
214.
ZieglerDK, HassaneinRS, KodanazA, . Circadian rhythms of plasma cortisol in migraine. J Neurol Neurosurg Psychiatry. 1979;42:741–748.
215.
MerikangasKR, StevensDE, MerikangasJR, . Tyramine conjugation deficit in migraine, tension-type headache, and depression. Biol Psychiatry. 1995;38:730–736.
216.
JarmanJ, DaviesP, FernandezM, . Platelet [3H]imipramine binding in migraine and tension headache in relation to depression. J Psychiatr Res. 1991;25:205–211.
217.
D'AndreaG, WelchK, RiddleJ, . Platelet serotonin metabolism and ultrastructure in migraine. Arch Neurol. 1989;46:1187–1189.
218.
MeltzerH, LowyM.The serotonin hypothesis of depression. In: MeltzerH, ed. Psychopharmacology: the third generation of progress.New York, NY: Raven Press; 1987:513–526.
219.
BuchsbaumMS, CourseyRD, MurphyDL.The biochemical high-risk paradigm: behavioural and familial correlates of low platelets monoamine oxidase activity. Science. 1976;194:339–341.
220.
RubinoE, FerreroM, RaineroI, . Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia. 2009;29:818–825.
221.
SamaanZ, FarmerA.Migraine and depression: connecting the dots. Mind and Brain, The Journal of Psychiatry. 2010;1:55–64.
222.
LiptonRB, DodickD, SadovskyR, . A selfadministered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61:375–382.
223.
SamaanZ, MacGregorEA, DowsonA, . Diagnosing migraine in research and clinical settings: development and validation of the Structured Migraine Interview (SMI). BMC Neurol. 2010;10:7.
224.
LamplC, SchweigerC.Antidepressants for migraine prophylaxis. European Neurological Journal. 2010;2:83–87.
225.
OlfosonM, MarcusSC, DrussB, . National trends in the outpatient treatment of depression. JAMA. 2002;287:203–209.
226.
MurrayTJ.Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525–527.
227.
World Health Organization, Atlas of multiple sclerosis resources in the world 2008. Geneva, Switzerland: World Health Organization; 2008.
228.
Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11:328–337.
229.
PattenSB, BeckCA, WilliamsJV, . Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524–1527.
230.
MindenSL, OravJ, ReichP.Depression in multiple sclerosis. Gen Hosp Psychiatry. 1987;9:426–434.
231.
SadovnickAD, RemickRA, AllenJ, . Depression and multiple sclerosis. Neurology. 1996;46:628–632.
SadovnickAD, EisenK, EbersGC, . Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193–1196.
234.
Bronnum-HansenH, StenagerE, Nylev StenagerE, . Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1457–1459.
235.
Koch-HenriksenN, Bronnum-HansenH, StenagerE.Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry. 1998;65:56–59.
236.
StenagerEN, StenagerE, Koch-HenriksenN, . Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry. 1992;55:542–545.
237.
FeinsteinA, RoyP, LobaughN, . Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586–590.
238.
MohrDC, GoodkinDE, LikoskyW, . Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–533.
239.
MohrDC, GoodkinDE, IslarJ, . Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclero sis. Arch Neurol. 2001;58:1081–1086.
240.
FeinsteinA, FeinsteinK, GrayT, . Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol. 1997;54:1116–1121.
241.
PattenS.Diagnosing depression in MS in the face of overlapping symptoms. Int MS J. 2010;17:3–5.
242.
BarakY, UrE, AchironA.Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci. 1999;11:271–273.
243.
BenedettiF, CamporiE, ColomboC, . Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2004;16:364–366.
244.
ScottTF, NussbaumP, McConnellH, . Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res. 1995;17:421–422.
245.
EhdeDM, KraftGH, ChwastiakL, . Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30:40–48.
246.
SchifferRB, WinemanNM.Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493–1497.
247.
MohrDC, BoudewynAC, GoodkinDE, . Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942–949.
248.
PattenSB.Antidepressant treatment for major depression in multiple sclerosis: the evolving efficacy literature. International Journal of MS Care. 2009;11:174–179.
249.
MohrDC, GoodkinDE.Treatment of depression in multiple sclerosis: review and meta-analysis. Clinical Psychology: Science and Practice. 1999;6:1–9.
250.
SchifferRB, WinemanNM, WeitkampLR.Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143:94–95.
251.
FisherRS, van Emde BoasW, BlumeW, . Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–472.
252.
SanderJW.The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003;16:165–170.
253.
MulaM, SchmitzB, JauchR, . On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav. 2008;13:658–661.
254.
KannerAM.Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry. 2003;54:388–398.
255.
MendezMF, DossRC, TaylorJL, . Depression in epilepsy. Relationship to seizures and anticonvulsant therapy. J Nerv Ment Dis. 1993;181:444–447.
256.
HesdorfferDC, HauserWA, AnnegersJF, . Major depression is a risk factor for seizures in older adults. Ann Neurol. 2000;47:246–249.
257.
ForsgrenL, NystromL.An incident case-referent study of epileptic seizures in adults. Epilepsy Res. 1990;6:66–81.
258.
MendezMF, EngebritB, DossR, . The relationship of epileptic auras and psychological attributes. J Neuropsychiatry Clin Neurosci. 1996;8:287–292.
259.
GilliamFG, SantosJ, VahleV, . Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction?Epilepsia. 2004;45:(suppl 2)28–33.
260.
KannerAM.Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol. 2008;21:190–194.
261.
RobertsonMM, TrimbleMR.Depressive illness in patients with epilepsy: a review. Epilepsia. 1983;24:(suppl 2)S109–S116.
262.
MulaM, SanderJW.Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30:555–567.
263.
KalininVV.Suicidality and antiepileptic drugs: is there a link? Drug Saf. 2007;30:123–142.
264.
JobePC, MishraPK, Adams-CurtisLE, . The genetically epilepsy-prone rat (GEPR). Ital J Neurol Sci.1995;16:91–99.
265.
KannerAM.Depression and epilepsy: do glucocorticoids and glutamate explain their relationship? Curr Neurol Neurosci Rep. 2009;9:307–312.
266.
KannerAM.Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci. 2008;10:39–45.
267.
PinedaE, ShinD, SankarR, . Comorbidity between epilepsy and depression: experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia. 2010;51:(suppl 3)110–114.
268.
PisaniF, SpinaE, OteriG.Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia. 1999;40:(suppl 10)S48–S56.
MulaM.The clinical spectrum of bipolar symptoms in epilepsy: a critical reappraisal. Postgrad Med. 2010;122:17–23.
271.
MazzaM, Di NicolaM, Della MarcaG, . Bipolar disorder and epilepsy: a bidirectional relation? Neurobiological underpinnings, current hypotheses, and future research directions. Neuroscientist. 2007;13:392–404.
272.
RobertsonMM, TrimbleMR.The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord. 1985;9:127–136.
273.
HovorkaJ, HermanE, NemcováII. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav. 2000;1:444–447.
274.
SpecchioLM, IudiceA, SpecchioN, . Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol. 2004;27:133–136.
275.
DeVaneCL.Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol. 1999;19:443–466.
276.
EttingerAB, KustraRP, HammerAE.Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007;10:148–154.
277.
FakhouryTA, MillerJM, HammerAE, . Effects of lamotrigine on mood in older adults with epilepsy and comorbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging. 2008;25:955–962.
278.
BlumerD, MontourisG, HermannB.Psychiatric morbidity in seizure patients on a neurodiagnostic monitoring unit. J Neuropsychiatry Clin Neurosci. 1995;7:445–456.
279.
RamaratnamS, BakerGA, GoldsteinLH.Psychological treatments for epilepsy. Cochrane Database Syst Rev.2008;(3):CD002029.
280.
DavisGR, ArmstrongHEJr, DonovanDM, . Cognitive-behavioral treatment of depressed affect among epileptics: preliminary findings. J Clin Psychol. 1984;40:930–935.
281.
MartinovicZ, SimonovicP, DjokicR.Preventing depression in adolescents with epilepsy. Epilepsy Behav. 2006;9:619–624.
282.
SavardG, AndermannLF, ReutensD, . Epilepsy, surgical treatment and postoperative psychiatric complications: a re-evaluation of the evidence. In: TrimbleMR, SchmidtB, eds. Forced normalization and alternative psychosis of epilepsy.Petersfield, United Kingdom: Wrightson Biomedical; 1998:179–192.
283.
RobertsonMM.Forced normalization and the aetiology of depression in epilepsy. In: TrimbleMR, SchmidtB, eds. Forced normalization and alternative psychosis of epilepsy.Petersfield, United Kingdom: Wrightson Biomedical; 1998:143–167.
284.
KannerAM, KozakAM, FreyM.The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav. 2000;1:100–105.
285.
SackeimHA.The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT. 1999;15:5–26.
286.
CoffeyCE, LuckeJ, WeinerRD, . Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biol Psychiatry. 1995;37:777–788.
287.
A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology. 1995;45:224–230.
288.
GeorgeMS, RushAJ, MarangellLB, . A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364–373.
289.
SawkaAM, ThabaneL, PapaioannouA, . The number of Canadian men and women needed to be screened to detect a case of osteoporosis: a population based study from the Canadian Multicentre Osteoporosis Study (CaMos). J Bone Miner Res. 2004;19:S368.
290.
LookerAC, MeltonLJ3rd, HarrisTB, . Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res. 2010;25:64–71.
291.
DohertyDA, SandersKM, KotowiczMA, . Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int. 2001;12:16–23.
292.
CummingsSR, BlackDM, RubinSM.Lifetime risks of hip, Colles,’ or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445–2448.
293.
MeltonLJ3rd, ChrischillesEA, CooperC, . Perspective. How many women have osteoporosis? J Bone Miner Res. 1992;7:1005–1010.
294.
World Health Organization. The world health report 2001: mental health: new understanding, new hope.Geneva, Switzerland: World Health Organization; 2001.
295.
TaylorV, McKinnonMC, MacdonaldK, . Adults with mood disorders have an increased risk profile for cardiovascular disease within the first two years of treatment. Can J Psychiatry. 2010;55:362–368.
296.
ZiereG, DielemanJP, van der CammenTJ, . Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28:411–417.
297.
DiemSJ, BlackwellTL, StoneKL, . Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167:1240–1245.
298.
RichardsJB, PapaioannouA, AdachiJD, . Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–194.
299.
CauleyJA, FullmanRL, StoneKL, . Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int. 2005;16:1525–1537.
300.
MichelsonD, StratakisC, HillL, . Bone mineral density in women with depression. N Eng J Med.1996;335:1176–1181.
301.
EskandariF, MartinezPE, TorvikS, . Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329–2336.
302.
PetronijevicM, PetronijevicN, IvkovicM, . Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone. 2008;42:582–590.
303.
KinjoM, SetoguchiS, SchneeweissS, . Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005;118:1414.
304.
BoltonJM, TargownikLE, LeungS, . Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31:56–60.
305.
PlengeP, RafaelsenOJ.Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psychiatr Scand. 1982;66:361–373.
306.
BliziotesMM, EshlemanAJ, ZhangXW, . Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29:477–486.
307.
BattaglinoR, FuJ, SpateU, . Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19:1420–1431.
308.
WardenSJ, BliziotesMM, WirenKM, . Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol. 2005;242:1–9.
309.
CizzaG, RavnP, ChrousosGP, . Depression: a major, unrecognized risk factor for osteoporosis?Trends Endocrinol Metab. 2001;12:198–203.
310.
SpanglerL, ScholesD, BrunnerRL, . Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008;23:567–574.
311.
ReginsterJY, DeroisyR, PaulI, . Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas. 1999;33:133–137.
312.
WhitsonHE, SandersL, PieperCF, . Depressive symptomatology and fracture risk in communitydwelling older men and women. Aging Clin Exp Res. 2008;20:585–592.
313.
LiuB, AndersonG, MittmannN, . Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303–1307.
314.
HaneyEM, ChanBK, DiemSJ, . Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007; 67:1246–1251.
315.
JordeR, SneveM, FigenschauY, . Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008;264:599–609.
316.
HowlandRH.VitaminDand depression. J Psychosoc Nurs Ment Health Serv. 2011;49:15–18.
317.
PapaioannouA, MorinS, CheungAM, . 2010clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182:1864–1873.
